To the Editor, Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphoma that predominantly affects older adults, with a median age at diagnosis of approximately 67 years and a marked male predominance [1, 2]. Treatment outcomes have improved substantially over the past two decades with the incorporation of rituximab, cytarabine-based induction and autologous stem cell transplantation (ASCT) in selected patients [3], and Bruton tyrosine kinase inhibitors (BTKis) [4].
John Vaughn
Yuma
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with John
Contact John, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack